Fred Alger Management LLC Raises Stake in Repligen Corporation $RGEN

Fred Alger Management LLC raised its position in Repligen Corporation (NASDAQ:RGEN) by 154.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 911,527 shares of the biotechnology company’s stock after acquiring an additional 553,105 shares during the quarter. Fred Alger Management LLC’s holdings in Repligen were worth $149,363,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in RGEN. Measured Wealth Private Client Group LLC purchased a new position in Repligen in the third quarter worth approximately $29,000. Bayforest Capital Ltd purchased a new position in Repligen in the fourth quarter worth approximately $32,000. Rachor Investment Advisory Services LLC purchased a new position in Repligen in the fourth quarter worth approximately $33,000. Los Angeles Capital Management LLC purchased a new position in Repligen in the fourth quarter worth approximately $36,000. Finally, Farther Finance Advisors LLC lifted its stake in Repligen by 61.8% in the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after acquiring an additional 128 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the subject of a number of recent research reports. Barclays lifted their price target on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. KeyCorp reiterated an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. Wells Fargo & Company decreased their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. UBS Group decreased their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Wednesday, February 25th. Finally, Canaccord Genuity Group reduced their price objective on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $164.64.

Repligen Stock Up 0.6%

Shares of NASDAQ:RGEN opened at $131.69 on Wednesday. The company has a market capitalization of $7.43 billion, a PE ratio of 146.32, a P/E/G ratio of 2.52 and a beta of 1.09. The company has a current ratio of 9.20, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $175.77. The firm has a 50 day simple moving average of $120.77 and a 200-day simple moving average of $137.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.10. The business had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The company’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.39 EPS. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. On average, equities analysts predict that Repligen Corporation will post 1.99 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.